DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Healthy
Interventions: DRUG: Treatment A (rosuvastatin)|DRUG: Treatment B (LX4211)|DRUG: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Sponsor: Lexicon Pharmaceuticals